GlassScriptPhysician profile
Felipe Novoa
NPI 1770905283
$110,171.58
in general payments reported to CMS, 2019-2025
24 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,603 · 2022: $14K · 2023: $19K · 2024: $40K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Travel and Lodging: $27K · Food and Beverage: $7,466 · Consulting Fee: $5,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,752.00 |
| Travel and Lodging | $26,528.96 |
| Food and Beverage | $7,465.53 |
| Consulting Fee | $5,942.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $65,771.60 | 2023-2025 | Ojjaara, Shingrix, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $26,107.69 | 2022-2025 | Reblozyl |
| Celgene Corporation | $13,778.36 | 2021-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $1,402.50 | 2025 | |
| Pfizer INC. | $735.21 | 2023 | |
| Cti Biopharma Corp. | $700.00 | 2022 | |
| Servier Pharmaceuticals LLC | $353.80 | 2024 | |
| Novartis Pharmaceuticals Corporation | $297.29 | 2021-2025 | |
| Seagen INC. | $132.14 | 2021 | |
| Adaptive Biotechnologies Corporation | $123.89 | 2023-2025 | Clonoseq |
| Astellas Pharma US INC | $115.82 | 2023-2024 | Cresemba, Xospata |
| Stemline Therapeutics INC. | $94.47 | 2024-2025 | Elzonris |
| Genentech, INC. | $94.19 | 2022 | |
| Sobi, INC | $93.42 | 2025 | |
| Genzyme Corporation | $82.52 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $60.75 | 2025 | Rytelo |
| Blueprint Medicines Corporation | $56.64 | 2025 | Ayvakit |
| Janssen Biotech, INC. | $53.66 | 2021-2023 | Tecvayli, Darzalex |
| Apellis Pharmaceuticals, INC. | $26.50 | 2023 | Empaveli |
| Genentech USA, INC. | $25.55 | 2025 | Venclexta |
| Incyte Corporation | $20.03 | 2025 | Niktimvo |
| Daiichi Sankyo INC. | $16.23 | 2025 | Vanflyta |
| Janssen Pharmaceuticals, INC | $15.89 | 2021 | |
| Amgen INC. | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felipe Novoa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.